GlassScriptPhysician profile
Ashish Dwary
NPI 1649561473
$35,863.20
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,050 · 2021: $7,679 · 2022: $2,575 · 2023: $53.35 · 2024: $7,841 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $3,368 · Honoraria: $2,100 · Food and Beverage: $698 · Education: $38.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,355.00 |
| Travel and Lodging | $3,367.56 |
| Honoraria | $2,100.00 |
| Food and Beverage | $698.13 |
| Education | $38.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,232.50 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| Exelixis INC. | $3,551.43 | 2025 | Cabometyx |
| G1 Therapeutics, INC. | $3,000.00 | 2021-2022 | |
| Geron Corporation | $2,653.86 | 2025 | Imetelstat |
| Glaxosmithkline, LLC. | $1,964.79 | 2021-2025 | Blenrep |
| Karyopharm Therapeutics INC. | $1,820.70 | 2025 | Xpovio |
| Pfizer INC. | $1,250.00 | 2021 | |
| Daiichi Sankyo INC. | $1,200.00 | 2022-2025 | Vanflyta |
| Immunomedics, INC. | $1,050.00 | 2020 | |
| Incyte Corporation | $860.00 | 2025 | Zynyz |
| Beigene, LTD. | $525.00 | 2021 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Sobi, INC | $200.00 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.00 | 2023 | Blincyto |
| Genzyme Corporation | $35.59 | 2025 | |
| Astellas Pharma US INC | $32.38 | 2025 | Vyloy |
| Abbvie INC. | $26.64 | 2025 | |
| Kite Pharma, INC. | $23.92 | 2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Welireg |
| Novartis Pharmaceuticals Corporation | $17.43 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $17.35 | 2023 | Imbruvica |
| Tactile Systems Technology INC | $15.60 | 2024 | Flexitouch Plus, Entre Plus |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Dwary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.